NCT02516371

Brief Summary

This study aims to exam the subpopulation of lymphocytes and evaluate the clinico-pathologic correlations.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable cancer

Timeline
Completed

Started Aug 2015

Typical duration for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 1, 2015

Completed
Same day until next milestone

Study Start

First participant enrolled

August 1, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 5, 2015

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

August 26, 2015

Status Verified

August 1, 2015

Enrollment Period

10 months

First QC Date

August 1, 2015

Last Update Submit

August 25, 2015

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

  • response rate after cancer treatment with chemotherapy

    6 months after chemotherapy

Study Arms (1)

lymphocytes

OTHER

To evaluate the subpopulation of lymphocytes in cancer patients

Other: lymphocyte

Interventions

lymphocyteOTHER

To evaluate the subpopulation of lymphocytes in cancer patients

Also known as: subpopulation of lymphocytes in cancer patients
lymphocytes

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • cancer patients of Uijeongbu St. Mary's Hospital
  • never treated with chemotherapy
  • Age between 20\~80 years-

You may not qualify if:

  • treated with chemotherapy before
  • No informed consent form

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Uijeongbu St. Mary's hospital, the Catholic university of Korea

Uijeongbu-si, Gyounggido, 480-130, South Korea

RECRUITING

MeSH Terms

Conditions

Neoplasms

Interventions

Lymphocyte Count

Intervention Hierarchy (Ancestors)

Leukocyte CountBlood Cell CountCell CountCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHematologic TestsInvestigative TechniquesCell Physiological PhenomenaBlood Physiological PhenomenaCirculatory and Respiratory Physiological Phenomena

Study Officials

  • Yoon Ho Ko, MD, PhD

    Uijeongbu St. Mary's Hospital, The Catholic University of Korea

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yoon Ho Ko, MD, PhD

CONTACT

82-31-820-3985koyoonho@catholic.ac.kr

Der Sheng Sun, MD, PhD

CONTACT

82-31-820-3584ds-sun@hanmail.net

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Clinical assistant professor

Study Record Dates

First Submitted

August 1, 2015

First Posted

August 5, 2015

Study Start

August 1, 2015

Primary Completion

June 1, 2016

Study Completion

December 1, 2018

Last Updated

August 26, 2015

Record last verified: 2015-08

Locations

KR(1)